News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
327,451 Results
Type
Article (19572)
Company Profile (139)
Press Release (307740)
Section
Business (105167)
Career Advice (866)
Deals (18491)
Drug Delivery (90)
Drug Development (50620)
Employer Resources (79)
FDA (7628)
Job Trends (7715)
News (185467)
Policy (17291)
Tag
Academia (726)
Alliances (27686)
Alzheimer's disease (560)
Approvals (7596)
Artificial intelligence (81)
Bankruptcy (172)
Best Places to Work (5503)
Biosimilars (67)
Biotechnology (62)
Cancer (545)
Cardiovascular disease (60)
Career advice (704)
Cell therapy (83)
Clinical research (41721)
Collaboration (213)
Compensation (69)
COVID-19 (1073)
C-suite (60)
Data (616)
Diabetes (94)
Diagnostics (1716)
Drug pricing (91)
Earnings (38277)
Employer resources (73)
Events (47564)
Executive appointments (198)
FDA (7887)
Funding (153)
Gene therapy (86)
GLP-1 (483)
Government (1796)
Healthcare (5852)
Infectious disease (1120)
Inflammatory bowel disease (67)
Interviews (114)
IPO (7289)
Job creations (2429)
Job search strategy (645)
Layoffs (252)
Legal (4079)
Lung cancer (96)
Manufacturing (128)
Medical device (1946)
Medtech (1949)
Mergers & acquisitions (11236)
Metabolic disorders (325)
Neuroscience (724)
NextGen Class of 2024 (2347)
Non-profit (901)
Northern California (664)
Obesity (209)
Opinion (174)
Patents (69)
People (32890)
Pharmaceutical (75)
Phase I (12996)
Phase II (17659)
Phase III (14222)
Pipeline (280)
Policy (70)
Postmarket research (1609)
Preclinical (4560)
Radiopharmaceuticals (155)
Rare diseases (137)
Real estate (3164)
Regulatory (12113)
Research institute (815)
Resumes & cover letters (138)
Southern California (614)
Startups (2005)
United States (6087)
Vaccines (210)
Weight loss (183)
Date
Today (62)
Last 7 days (419)
Last 30 days (1848)
Last 365 days (17908)
2024 (16369)
2023 (19635)
2022 (25869)
2021 (26641)
2020 (24873)
2019 (20058)
2018 (15587)
2017 (17253)
2016 (16202)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (406)
Asia (24447)
Australia (3146)
California (1490)
Canada (742)
China (145)
Colorado (62)
Connecticut (60)
Europe (50455)
Florida (209)
Illinois (146)
Indiana (115)
Japan (56)
Kansas (56)
Maryland (228)
Massachusetts (1263)
Minnesota (87)
New Jersey (576)
New York (436)
North Carolina (357)
Northern California (664)
Ohio (63)
Pennsylvania (368)
South America (603)
Southern California (614)
Texas (193)
Washington State (143)
327,451 Results for "amryt pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Former Amryt Pharma Leadership Team join Poolbeg
Poolbeg Pharma, a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces the appointment of key former executives of Amryt Pharma plc to its leadership team.
November 9, 2023
·
6 min read
Deals
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici.
March 22, 2023
·
6 min read
FDA
Chiesi’s $1.25B Amryt Buy Pays Off with FDA Approval of Filsuvez
Chiesi Global Rare Diseases gained access to the Filsuvez topical gel in January 2023, when it bought Amryt Pharma. Tuesday’s approval comes nearly two years after an initial rejection by the regulator.
December 20, 2023
·
2 min read
·
Tristan Manalac
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Deals
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
Chiesi Farmaceutici S.p.A. announced the completion of the acquisition of Amryt Pharma Plc, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases.
April 12, 2023
·
3 min read
Deals
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
Chiesi Farmaceutici S.p.A. and Amryt Pharma Plc announced that the companies have entered into a definitive agreement under which Chiesi will acquire Amryt.
January 8, 2023
·
12 min read
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
·
2 min read
·
Tristan Manalac
Rare diseases
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.
November 20, 2024
·
7 min read
·
Heather McKenzie
Opinion
Opinion: A Small Pharma Mindset Can Reshape Big Pharma and Improve Patient Care
An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.
September 12, 2024
·
3 min read
·
Jill Marie Drury
Layoffs
Athira Pharma to Lay Off 70% of Workforce
Athira Pharma will cut about 49 positions, including two people in the C-suite. The announcement follows the company’s disappointing results for its investigational Alzheimer’s therapy.
September 23, 2024
·
1 min read
·
Angela Gabriel
1 of 32,746
Next
